Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Tigecycline

Nature Reviews Drug Discovery volume 4, pages 809–810 (2005)Cite this article

Abstract

Tigecycline (Tygacil;Wyeth) was approved by the US FDA for the treatment of a range of bacterial infections in June 2005. It is the first in a new generation of tetracyclines known as glycylcyclines, which have been developed to overcome the problems of resistance to earlier tetracyclines.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Tigecycline.

References

  1. Walsh, C. Where will new antibiotics come from? Nature. Rev. Microbiol. 1, 65–69 (2003).

    Article  CAS  Google Scholar 

  2. Chopra, I. Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1, 464–469 (2001).

    Article  CAS  Google Scholar 

  3. Sum, P. E. & Petersen, P. Synthesis and structure–activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9, 1459–1462 (1999).

    Article  CAS  Google Scholar 

  4. Petersen, P. J. et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43, 738–744 (1999).

    Article  CAS  Google Scholar 

  5. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021821lbl.pdf> (2005).

  6. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309–317 (2004).

    Article  Google Scholar 

  7. Wenzel, R. P. & Edmond, M. B. The impact of hospital-acquired bloodstream infections. Emerging Infect. Dis. 7, 174–177 (2001).

    Article  CAS  Google Scholar 

  8. Ibrahim, E. H. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118, 146–155 (2000).

    Article  CAS  Google Scholar 

  9. Doern, G. V. et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41, 139–148 (2005).

    Article  CAS  Google Scholar 

  10. Noskin, G. A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41, s303–s314 (2005).

    Article  CAS  Google Scholar 

  11. Ellis-Grosse, E. J. et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vanco-mycin-aztreonam. Clin. Infect. Dis. 41, s341–353 (2005).

    Article  CAS  Google Scholar 

  12. Babinchak, T. et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41, s354–s367 (2005).

    Article  CAS  Google Scholar 

  13. IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA

    Richard Wenzel, Guy Bate & Peter Kirkpatrick

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Richard Wenzel, Guy Bate & Peter Kirkpatrick

  3. Nature Reviews Drug Discovery, UK

    Richard Wenzel, Guy Bate & Peter Kirkpatrick

Authors
  1. Richard Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wenzel, R., Bate, G. & Kirkpatrick, P. Tigecycline. Nat Rev Drug Discov 4, 809–810 (2005). https://doi.org/10.1038/nrd1857

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1857

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing